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INTRODUCTION 
In  recent  times,  there  has  been  a  tremendous  change  in  the  
lifestyle  of people.    These  changes  do   have  an  impact  on  the  
health  of  the   people   and   make  them  prone   to    certain   diseases  
and  its  complications.  Polycystic  ovarian  syndrome (PCOS)  is  one  
such  disease.  It  is  a  multisystem endocrine  syndrome .  This   is  due  
to  the  ovarian  effect  resulting  in  menstrual  disturbances  and  
various  metabolic  disturbances  like  hyperandrogenism  and  obesity.   
PCOS  is  more  common  between  15-25yrs1  of  age.  It  has  
genetic  and  familial  tendency.  PCOS  includes   chronic  anovulation,  
polycystic  ovaries  on  ultrasound (USG) ,   hyperandrogenism,  raised  
LH   levels ,  low  FSH levels,   elevated  fasting  insulin, low  serum  
binding  hormone  globulin.  PCOS  may  be autosomal  dominant  
inherited. Prevalence  of PCOS  in  reproductive  age  group  is  5-10%2. 
Polycystic   ovarian   syndrome   is   associated   with  metabolic 
disturbances.  Insulin  resistance,  obesity   all  contribute  for  the  
metabolic  disturbances.  They  have   high   chances   of  metabolic  
syndrome  characterized  by  hypertension, increased   fasting   glucose,  
dyslipidemia   and   increased   waist  circumference. 
 
 
 
10 
 
Metabolic  syndrome  is   prevalent  in  women  with  PCOS  and  
it  is  on  the  rise  due  to  alterations  in  the  lifestyle . Therefore  it  is  
necessary  for   PCOS  women  to  be  screened  for  metabolic  
syndrome  to prevent  long  term  complications  like cardiovascular  
disease  ,   type  2  diabetes  mellitus  and  endometrial   cancer. 
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AIM  OF  THE  STUDY 
                  To  study  the  prevalence  of  metabolic  syndrome  among  
patients  with  PCOS  attending  Gynaecology  outpatient  department,  
OBG  Department,  KMCH  using  clinical  features  and  biochemical  
tests   during  the  period  May 2013  to   November  2013.  
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REVIEW   OF  LITERATURE 
Polycystic   ovaries  were   recognized  from  mid  18th  century.  
They  were  known  as  multicystic  ovaries  or  sclerotic  ovaries.   In  
the  early  20th  century,  polycystic  ovaries  were  considered  as  a  
result  of  inflammation   due  to  infection  and  congestion. 
               Michael  L. Leventhal   and   Irving  F. Stein  together  
described  a  syndrome  associated  with  anovulation28  in 1935.   They  
described  that  patients   with  PCOS  had  hirsuitism  and   amenorrhea.  
They proposed   the  theory  that  the  thickened  ovarian   capsule  
prevented  the  follicles  from reaching  and  escaping   the  surface  of   
the  ovary . 
          The  characteristic  polycystic  ovaries  results  when  chronic  
anovulation   is  present  for  a   long  period  of  time.  About  75%  of   
anovulatory  women  will have  polycystic  ovaries.The  histologic  
picture of  Stein- Leventhal  ovary 30  is   as  follows 
 Cross sectional  area  is  twice  as  normal  ovaries. 
 Sub -cortical   stroma   is   5%  thicker. 
 Developing   and   atretic  follicles  are  double  in  number. 
 Tunica   is  50%  thicker  and  has  more  collagen. 
 Hilar   cell  nests  are  four  fold  greater  in  number. 
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PATHOPHYSIOLOGY 
   PCOS  is  a  complex  multisystem  disorder,  where   numerous   
genetic  and  environmental   factors  contribute  to  its  
pathophysiology.   Polycystic  ovaries  and  clinical  features  of   PCOS  
are  due  to  disturbances  in  the  development  of   follicle  causing   
anovulation.  
 Gonadotropin  Secretion   And  Action: 
  PCOS  women  have   increased   serum   Leutenising  
Hormone(LH),  low  Follicle  Stimulating   Hormone (FSH)   levels,  
and  raised  LH: FSH  ratios.   Both   increased   pulse   frequency   and  
amplitude  of   LH contributes  for  raised  LH  levels.   The  pulse   
frequency  of  LH  is  not as  constant  as  seen  in  normal   ovulatory   
women  , which  is  one  pulse  per  hour.  The  bioactivity25  of  LH  in  
PCOS  women  is  also  more.  The  response  of  LH  to  exogeneously  
given  GnRH  is  also  raised  in women  with  PCOS. 
FSH  levels  are  decreased.  The   decrease   is   due   to   increase   
in    pulse  frequency   of   GnRH.    Negative  feedback  of  estrones  
and   increased  levels  of   Inhibin-B   also contribute   to   the   decrease   
in  FSH.  
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Thus  excessive   LH32  secretion  is  an  important  cause  of  disrupted  
development   of  follicle   resulting   in  anovulatory  cycles. 
INSULIN   RESISTANCE      
  The   association   between   hyperandrogenism   and  glucose  
intolerance  was first  described  in 1921 by  Theirs  and Archard8 .  
They  reported  a  diabetic  women   with  beard .  Insulin  resistance   is   
a  feature  of    variety  of  conditions  like  type 2 diabetes,  obesity,  
pregnancy,  stress,  and  PCOS.  The  role  of  insulin  in  the  
pathogenesis  of  polycystic  ovarian  syndrome  was  first  suggested   
in 1980 . In   that  study  significant  correlation  was  demonstrated  
between  testosterone  and  basal levels  of  insulin.  They  also  
demonstrated  correlation  after  an  oral  glucose  load  between  
testosterone  and  insulin levels                                                             
 Insulin  resistance  is  said  to  be  present   when  the  actions  of   
either   endogeneous   or  exogeneously   given   insulin   are  not  
effective  on  fat,  muscle  and  adipose  tissue.   In  adipose  tissue  due  
to insulin  resistance  there  is hydrolysis  of  Triglycerides  and  
increased  free  fatty  acids .  In  muscle  there  is  decreased  glucose   
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utilization  and   increased  hepatic  gluconeogenesis   causing   elevated   
blood  glucose   and  compensatory   hyperinsulinemia. 
High  circulating    insulin   levels  cause   hyperandrogenism    in  
PCOS   women  by   two   mechanisms . Insulin  acts  on    theca  cells  
of  ovarian   stroma  through  insulin receptors  and  stimulates the  
production  of  androgens  from  ovaries.   It   inhibits   hepatic   Serum  
Hormone   Binding   Globulin (SHBG)  production.  
    Actions  of   insulin   are  mediated  through  its  receptors 26 by  
two  intracellular   pathways.   Metabolic  effects  are  mediated   
through   phosphatidyl  inositol  3-kinase pathway.  Proliferative  action  
is  mediated  through   mitogen – activated  protein  kinase  pathway.  In  
women  with  PCOS  activation  of  mitogen  pathway  by  insulin  is  
increased . there  is  also     resistance  in the  metabolic  pathway  of  
insulin  mediated  by   phosphatidyl-inositol 3-kinase.     
“ Thus insulin actions  can  be  selectively  inhibited  and 
enhanced  at the  same  time  via  different signaling  pathways” .  This  
explains the  mechanism  by which insulin stimulate hyperandrogenism  
in women,  who  are  insulin  resistant.  
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Insulin   and   androgens   together   lower   SHBG   causing   free  
androgen  levels  which  in  turn  aggravates  insulin  resistance.  Thus  
insulin  resistance  and   hyperinsulinemia  are  the  cause  of   
hyperandrogenism.   
Insulin   and   hyperinsulinemia   are  important  factors  in  the  
pathophysiology  of    PCOS.    20-50%8   of  PCOS   women  have  no   
insulin   resistance   and      prevalence  of    PCOS   is   low  among  
women  who  have  insulin  resistance. After ovarian  wedge  resection  
sensitivity  of  insulin  is  not  changed.  Though   insulin   resistance  
and  hyperinsulinemia   contribute   major  portion  in  the   
pathophysiology   of   PCOS   they   are  not  the  primary   cause   in   
all  PCOS  women.  
HYPERANDROGENISM 
         Hyperandrogenism   is   important   feature  of   PCOS .  Excess   
androgen  is   produced  both  from  the  ovaries  and  adrenals   with  
major  contribution  from  the  ovaries.  Sixty percent  of  circulating   
androstenedione is  produced from the ovaries  and  the  rest  from  the  
adrenls . Sixty percent of  testosterone  is  also  produced   from  the   
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ovaries   and   the  rest  of   the     testosterone  are  produced   from  
peripheral  conversion of  androstenedione.21 
Important  reason  for  excess  production   of   androgen  from  
ovaries   in   PCOS  women  is  due  to   increased   LH   secretion ,  
increased  bioactivity  of  LH,  hyperinsulinemia  and   obesity.  Other  
factors  include  increased  volume of  theca   cells  due  to  increased   
ovarian  stroma,  increased  sensitivity  to  LH  and overexpression   of   
LH receptors.    
  High   local   androgens   are   responsible   for   the   
characteristic   polycystic ovaries.   Androgens    are  converted   to  
more   potent   androgen   by   5 alpha reductase.   This   potent   
androgen   cannot    be   further  converted    to  estrogen.     These   
androgens   further   inhibit   the    aromatase  activity  and   FSH    
stimulated   induction   of    LH  receptors   on   the   granulosa  cells.   
Thus  granulosa   cells   of   PCOS    patients   are   not   able   to   
produce    adequate  amount   of  estrogen ,   necessary  for  follicular  
development   causing   arrest   of   the  growth   before   full   
maturation.   
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  New   follicles   continue   to   grow   and    get   arrested    before    
full   maturation    which    results   in   multiple   small   follicular   
cysts.   These   follicular   cysts   are   surrounded   by    hyperplastic   
theca   cells.   Increased   ovarian    stroma   is   contributed   by   the   
atretic   follicles. 
Adrenal  androgens  like  androstenedione ,  DHEA , DHEA-S  
are  also  increased in  PCOS  patients .  Even  when  the  synthesis  of  
androgens   by  ovaries  were inhibited  by  GnRH  agonists,  adrenal  
androgens  remained  higher   in  PCOS  women   when  compared  with  
normal  women.    Adrenal  androgens  donot  have  any  intrinsic   
activity.  There   is  peripheral  conversion  of  adrenal  androgens  to  
testosterone.  This  peripheral   conversion  contributes  to  the  
pathophysiology  of  polycystic ovarian  syndrome. 
The  role  of  high  amount  of  local  androgen   levels  in  the  
pathophysiology  of  Polycystic ovarian syndrome   is   demonstrated   
by  wedge  resection  of  ovaries.30   Wedge  resection  of  ovaries  
resulted  in  decrease  in    production  of   androgens   by  ovaries.    
This  decrease    was  followed   by  the  return  of  normal  menstrual  
cycles .  It  can be concluded  that  high  amount  of   androgens   inhibit  
development   of  follicle and  also  inhibit  ovulation.   
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DIAGNOSIS OF  PCOS 
Polycystic ovarian  syndrome   is   not  a  specific disease. It is a   
syndrome   characterized   by   group   of   signs    and    symptoms.   
Clear  cut  definition  of  PCOS  is  important  because  of  the  
complications    associated   with   PCOS.   Women   with    PCOS  are  
at increased  risk   of getting  ,  cardiovascular   disease obesity ,  
endometrial  cancer,   dyslipidemia,    diabetes  mellitus,  hypertension.  
It  is also   important  to  diagnose  PCOS  because of  its health  
implications  in other  family  members  and  also  due  to  the  need of  
life  long   treatment 
In earlier  times  the disease was  described  based  on  hirsuitism ,  
menstrual  disturbances   and  enlarged  ovaries. Only in recent  times  
the  role of  insulin resistance  in  the  pathopysiology  of  PCOS  have  
been   recognized.   The  attention  is  now  being  focused  on  the  
metabolic  consequences of  the  disease.15 
CRITERIA  FOR  PCOS 
There  are  three    different  and  distinct   criterias  to define  
PCOS  till date. The  main   advantage   of  having  specific  criteria  for  
PCOS  is  for research  purposes . The  three  criterias   are   National   
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Institute  of  Child   Health   and Human  Development ,  Androgen  
excess  and  PCOS  society  criteria  and   American  Society for   
Human  Reproduction  (ASRM) held  in  Rotterdam,  the  Netherlands. 
The   first  to  define  PCOS  was   National  Institue  Of  Child  Health  
and  Human  Development(NICHD)  in  1990.   
1)   Hyperandrogenism  
           2)  Menstrual  dysfunction 
           3)  Exclusion  of  other  disorders   with  same  clinical  
symptoms 
The     second    was  defined   in   a    conference     in  2003  
conducted  by  the  European  Society  for  Human  Reproduction   and  
Embryology (ESHRE)  and  American   Society  for  Reproductive  
Medicine (ASRM)  in  Rotterdam28,  The  Netherlands .  It   concluded  
that  atleast  two  of  the  three  major  criteria  should  be  present. 
            1)  Oligomenorrhoea  
                   2)    Clinical  or  biochemical    hyperandrogenism 
  3)   Polycystic  ovaries  (USG) , excluding   other  
  androgen   excess   disorders                
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The  third  was  defined  by  Androgen Excess  and  Polycystic  
ovarian  syndrome Society (AE-PCOS)  in  2006. 
1)  Hyperandrogenism 
2)  Oligomenorrhoea  or   anovulation   and  or polycystic  
ovaries 
3) Exclusion  of  other  androgen  excess  disorders. 
All  these  criterias  were  designed  only  to  refine  the  diagnosis  
of  PCOS,and  for  purpose  of  research. NICHD  criteria  says  that  
both  hyperandrogenism  and  menstrual  dysfunction  are  necessary  for  
diagnosis  of  PCOS.    
The  Rotterdam  criteria  2003  says  that   polycystic  ovaries, are  
evidence  of  ovulatory  dysfunction  and  should  be  included  in  the  
criteria.   It  also   highlights  that  hirsuitism  and  menstrual  
abnormalities  can  be  either  present  or  absent. “AE-PCOS 2006”  
criteria  says  that  polycystic  ovaries  can  be   included   but  still  
hyperandrogenism  must  be   present  for  any  patient  to  be 
categorized  as  PCOS.    
The  use  of  different  criterias  to  define  PCOS  creates  
confusion  among  patiens and clinicians.  “National Institute of Health 
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Evidence-based Methodology Workshop on PCOS in December 2012 
concluded that the Rotterdam criteria should be adopted for now 
because it is the most inclusive” 27 
FEATURES   OF  PCOS 
Hyperandrogenism 
Hyperandrogenism  can  be  either  clinical  or  biochemical.   
Hirsuitism , acne  and  androgenic  alopecia  contribute  to  clinical   
hyperandrogenism .   All  these  features are  due  to  the  effect  of  
androgens  on  the  pilosebaceous  unit.  Clinical  and   biochemical  
hyperandrogenism  are  poorly  related   as  the  pilosebaceous  unit’s  
sensitivity  is  not  same  among  all  individuals.  
Clinical  Hyperandrogenism : 
Clinical   hyperandrogenism   is  characterized   by   hirsuitism,   
acne  ,  virilization , temporal  balding  and  decreased   muscle  mass. 
 HIRSUITISM 
           It is  defined  as  excessive  growth  of  hair  on  face  and  body  
in male  pattern  in  women.  It  is  necessary  to  understand  the  
embryology  of  hair  and  hair  growth.  It is   from  the  follicle  the  
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hair  grows.  Hair follicle,  sebaceous  gland,  and  arrector  pili  muscle  
together  constitute  the  pilosebaceous    unit.  This  pilosebaceous   unit  
is  sensitive  to  hormones ,  especially  the  more  potent  androgen  , 
Dihydrotestosterone(DHT).   5 alpha - reductase  converts  testosterone  
to  dihydrotestosterone .  It   is  DHT  which  is  responsible   for  
stimulation  of  hair  follicles,  so local  levels  of  5 alpha – reductase   
also  influence  the  stimulation  of  hair  follicle. 
Human  hair  is  of  two  types.  Vellus  and  terminal  hair. Vellus  
is  fine, soft,  and  short . It  is  not  pigmented .  It  is  usually   present  
over  face,  back  and  chest.  Terminal  hair  is  dark,  coarse  and  long.  
It   is  pigmented  and  is  present  over  the  scalp,  pubis  and  axilla.   
Excess   growth  of  the  terminal  hair  on  face, and  body  in  women   
is  called   hirsuitism.  It  is  due  to  the  excess amount  of  androgen.  
Sexual  hair  responds  to  sex  hormones. It grows  primarily  on  
the  chest,  pubis, axilla  and  lower  abdomen.   Androgens  stimulate   
growth  of  hair  follicles  making  it  thick,  dark  and  long  in   areas  
sensitive to androgen.  Testosterone  increases  the  pigmentation  and  
diameter  of  hair.  The  amount of  time  spent  by  terminal hair  in   the  
phase  of   anagen  is  increased by androgens  in  all  areas  excepet  
scalp 
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The  most  common  cause of  excessive  androgens  in  women   
is  PCOS. Hirsuitism  is  graded  by  modified  Ferriman –Gallwey  
score . 9 androgen  sensitive  areas  are  selected  and  a score of  1-4  is  
given  according  to  the  extent  of  hirsuitism.  A  score  of  6-831 
defines  hirsuitism.  
The  growth  of   hair  is   not  continuous.  It  is cyclic.  It  
undergoes  three  phases.  The  resting   phase  is   called  quiescent  
phase,  growth phase  is  called as  anagen  and   the  phase  of  
involution is  called  as  catagen. In  the   anagen  phase   hair  is  short   
and   loose.  Only  in  the  anagen   phase  hair  grows  to   its  
maximum.  Androgens  decreases  the  time  spent   by  hair   in anagen  
phase in  scalp   whereas   it increases  the   amount   of time   spent  by  
hair   in  anagen   phase  in  all   other  places  like  forearm  and   face. 
Nine  androgen  sensitive  areas  are  upper lip,  chin,  inter 
mammary area,  lower  abdomen,  midline  from  umbilicus  to  pubic 
symphysis,  forearm,   back  of  thigh,  interscapular region   and   
gluteal  region. 
In   hirsuitism  women,   60%   of   testosterone   and   
androstenedione   are  derived  from the  ovary  . The  rest  is  
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contributed   by  the  testosterone  which  is  produced  from   peripheral  
conversion. The  marker  for  peripheral    metaboliasm   of  androgen  is 
3 alpha  androstanediol  glucuronide.  This  3  alpha  androstanediol   
correlates  wellwith   5  alpha reductase  activity.    In  women  with  
hirsuitsm  with  normal  androgen  levels,  5alpha  reductase  is  
increased. 
Androgen    excess  disorders   and  chronic   anovulation   are   
the  most  common   cause   of   hirsuitism.    Adrenal  causes  are  
uncommon. 
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MODIFIED  FERRIMAN –GALLWEY  SCORE 
A  score  of  1-4 is given.  Scores  between  6-8  is  considered  
hirsuitism. 
Figure 1 
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Other  causes  of  hirsuitism  include   
 Classical  congenital  adrenal  hyperplasia 
 Non  classical  congenital  adrenal  hyperplasia 
 Cushing  syndrome 
 HAIR –AN syndrome 12 (Hyperandrogenism,  insulin  resistance,  
and  Acanthosis  nigricans) 
 Androgen  secreting  neoplasm 
 Idiopathic   hirsuitism 
 Hyperprolactinemia  
 Pregnancy luteoma 
 Drugs  like  Phenytoin,  Minoxidil  and  Diazoxide. 
Acne ,  alopecia,   temporal balding,   and  seborrhea  are  other  
clinical  signs  of  androgen  excess.  Virilization   is  present  if   there  
is  severe  amount  of  excess  androgen.  Virilization  signs  include  
deepening  of  voice,  breast  atrophy,  increased  muscle  mass,  and  
clitoromegaly.   
The   other  physical  signs  of  hyperandrogenism  includes   
galactorrhoea,  which   is  suggestive  of  hyperprolactinemia  and  
abdominopelvic   masses  suggestive  of  androgen   secreting  tumors. 
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Figure  2 
Hirsutism 
 
Excessive  overgrowth  of   terminal  hair  is  called  hirsuitism. 
Modified ferriman gallway  score  is used  to  define hirsuitism. 
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The    physical   signs  of    hyperandrogenism   reflect   the  
severity    of  androgen  excess.  All  women  with  hirsuitism  do  have  
an  increased  production  of  androgens,  both  testosterone  and   
androstendione 
 BIOCHEMICAL   HYPERANDROGENISM 
Dehydroepiandrosterone sulfate (DHEA-S), Testosterone,  
Dehydroepiandrosterone  sulfate (DHEA),  Dihydrotestosterone(DHT)  
and  Androstenedione  are  the  major  circulating  androgens in  women.  
Circulating  androgen   levels  and  the sensitivity  of hair  follicles  to  
the circulating  androgens  cause  hirsuitism. 
DHEA-S    is   produced   exclusively  by  adrenal  glands . 
DHEA  is  produced   by  both  ovaries  and  adrenals  .  DHEA  is  also   
produced   from   the  peripheral  conversion   of  DHEA-S.   
Androstenedione  is  produced  equally  by  ovaries  and  adrenals.  
DHEA-S,  DHEA and  Androstenedione  have  to  be  converted  to  
testosterone  for  them  to  exert   their  androgenic  actions. 
Testosterone   is  secreted  by  both  adrenals  and  ovaries.  
Peripheral  conversion  of  androstenedione   also  contribute  to 
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production  of testosterone.  It  is  the free testosterone  which is  
responsible  for  the androgenic  actions. 80%  of  testosterone  is  bound  
to  SHBG ,  19%  to  albumin and  only  1%  is  free.  Any  condition  
altering  the  amount  of  SHBG  will  affect  the  amount  of  free  
testosterone.  Most  of  the  serum   immunoassays  measure both  the  
free  and  bound   testosterone.    Serum  total  concentration  of  
testosterone  doesnot  reflect  the  amount  of androgen excess  as  
testosterone  is  converted  to  DHT  which  is more  potent  androgen  
and  has  a longer of  duration  than testosterone .   
DHEA-S  is  the marker  for  adrenal  androgens. It  remains  
stable  through out  day  and  night.  Though  DHEA-S   can be taken  as  
marker  of  hyperandrogenism  in  patients  with  PCOS  the  sensitivity  
and  specificity  is  very  less  for  it  to  be  considered    as  the   
diagnostic  marker  of  hyperandrogenism. 
Thus  for  clinical  purposes  hyperandrogenism  can  be  
identified  by  hirsuitism  itself   rather   than   measuring  the  amount  
of  androgens21. 
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OVULATORY  DYSFUNCTION 
Most  of  the  women  with  PCOS  have  menstrual  disturbances.  
About  80%10  of  them  have  ovulatory  dysfunction.  The  most  
common  abnormalities  are  oligoamenorrhoea  and  amenorrhoea.  The  
normal   inter -menstrual  period  is  21-  35  days.  
 Oligomenorrhoea   is  defined   as  absence   of  menses   for  a  
period   of  35-182 days.  Amenorrhoea   is   defined  as  absence  of  
menses  for  a  period   of  more than  182  days. 
Very  few  women  have   polymenorrhoea.   Polymenorrhoea  is 
regular  cycles occurring  less  than 25  days.  Only  2%8  of  PCOS  
women  have  polymenorrhoea.  About   15%8  of  women  with   
polycystic ovarian   syndrome  have  normal  menstrual  cycles. Other  
common  conditions  with  anovulatory  state  are   hyperthyroidism,  
hypothyroidism, hyperprolactinemia. 
Oligomenorrhoea  and   amenorrhoea   are   due  to  chronic  
anovulation.  Chronic  anovulation   is  due  to  increased  LH ,  low  
FSH,  high  amount  of  local  androgens  , increased  inhibin  levels.  
All  these  together   prevent  the  formation  of  follicle.  It   is followed  
by  atresia  of  follicles   leading  to  a  chronic  anovulatory  state 
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POLYCYSTIC  OVARIES : 
 Polycystic  ovaries  appear   macroscopically  as   enlarged  and  
lobulated  and   have  a  very  thick  capsule  with no  adhesions. 
 On  USG  they  appear  as  multiple  follicles  ,usually  more   
than  or  equal to  12  measuring  about  2-9mm  in  diameter.   
 They  are  located  along  the  border   giving  them   a  necklace  
pattern 
 ovarian  volume  is  increased  > 7 ml.   
 Atretic  follicles  are  also  visible  .  
  Stromal  hyperplasia  ,  thecal  hyperplasia  and   atretic  follicles  
contribute  to  the  increased  ovarian  volume5. 
Rotterdam  criteria  takes  into  consideration  only  the  number   
of  follicles  whereas  the   others  define  PCOS  by  considering  both  
number  of  follicles  and  also  the ovarian volume .  
Polycystic  ovaries  may  also  be  present  in  women  using  oral  
Contraceptives.  It  is  also  present  in  normal  women  who  have  
normal  menstrual  cycles. 
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Although  polycystic  ovaries   are   present  in  most  women  
with  PCOS,  the  important  point  to  be  noted  is,  polycystic  ovaries  
are  not  necessary  for  the  diagnosis  of  PCOS. 
POLYCYSTIC  OVARIES  ON  USG 
Twelve  or  more  follicles .  
Each  follicle  2-9mm in  diameter. 
Ovaraian  volume >10cm3 
Arranged  peripherally 
Figure  3 
 
POLYCYSTIC OVARIES(USG) 
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OTHER  FEATURES  OF  PCOS 
Insulin  Resistance: 
Most  of  women  with  PCOS  have   insulin resistance.  When 
compared with lean  women insulin resistance is more  in  obese  
women  . Insulin  resistance  can  be demonstrated  by  the  serum  
fasting  insulin  levels.  Levels  more  than  30microunits/ml  are 
suggestive  of  insulin  resistance.  Insulin  sensitivity  can  be identified  
by  fasting  glucose/insulin  ratio.   Sensitivity  is  reasonable  if  the  
ratio  is less than  4.5 .12 
Another  method  to  assess  the  insulin  sensitivity  is  by  
Homeostatic   model  assessment  of  insulin  resistance  (HOMA-IR) .  
Product  of  fasting  insulin  and  fasting  glucose  divided  by  
constant   22.5  gives  HOMA-IR.  Normal values   are  3-3.9.  Values  
greater  than  this  indicate  insulin  resistance.   
Insulin  resistance  can  also  be  assessed by  QUICKI20 , 
quantitative  insulin   sensitivity  check  index.  
Inverse  of  logarithmic  sum  of  glucose  and  insulin  gives  the  
value  of  QUICKI.  Normal   value   is  0.33.  OGTT  oral  glucose  
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tolerance  test  is  used  to  diagnose   glucose  tolerance  and  diabetes   
mellitus. 
OBESITY 
Obesity   is  an  important  feature  of  PCOS.  70%8 of  
PCOSwomen  are  obese  and  the  remaining  are  lean. Menstrual  
dysfunction,   infertility and hirsuitism  are  higher  in  obese  PCOS  
women  when  compared  with  lean PCOS  women. 
Obesity  itself  is  related  to insulin  resistance.  Intraabdominal  
obesity  is  highly correlated  with  insulin resistance .  Visceral  fat  is    
metabolically more  active  than  subcutaneous  fat  .Visceral fat   is  
sensitive  to   lipolysis  and releases  large  amount  of  fatty  acids.  
These  fatty acids   produce  large  amount  of  cytokines  like   leptin,  
interleukin -6,  and  tumor necrosis factor alpha.  All  these  cytokines  
are  involved  in  insulin resistance. 
Stein   Leventhal  initially  noted  the  association of  obesity   
with  the combination  of  anovulation,  polycystic ovaries  and  
hirsuitism.  
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OVARIAN  EFFECTS  OF  OBESITY 
Obesity  is  related  to  insulin resistance  .  Insulin  stimulates  
production   of  androgens  from   ovaries  . Multiple  growth  factors  
like  insulin growth  factor are   more  in obese  women.   These  growth  
factors  stimulate  the  production  of  androgens. They  also  inhibit  
aromatization   of  androgens  to  estrogens 
Hypothalamic  pituitary  Action    
Insulin   resistance  is  associated  with  the  effects   of  
hypothalamus.  Adipokines   like  leptin   play  very  important  role   in  
regulating  the  function  of  ovary.   This  can  be   demonstrated  in  
patients  with   anorexia   nervosa .   secretion  of  gonadotropin   is  
suppressed  in  them .   Gonadotropin  suppression  causes  loss  of  
ovulatory  function. 
Metabolic   effects: 
Obesity  is  related  with   increased  risk  of  metabolic  
disturbances.   Obesity  is  related  to  insulin resistance.   Influence of   
both   PCOS  and  obesity  on  insulin resistance is  independent  as   
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well  as have   additive  effects.  Dyslipidemia is  common  in  obese 
women  who   have  PCOS  than   lean  PCOS  women.       
Reproductive  effects: 
Obesity  as  such  doesnot   have  any  effect   on   the  
reproductive   functions,  except   for   causing  anovulation   and  
hirsuitism. Obesity  and  PCOS are  associated with  endometrial cancer.   
Obesity   is  associated  with   breast  cancer. 
INFERTILITY 
Due  to  chronic  anovulation , women  with  PCOS   donot  
conceive .  Infertility  is  common in  women  with  PCOS.  Endometrial  
abnormalities  and  quality  of   oocyte   also  contribute  to   the  causes 
of  infertility  in  addition   to  anovulation 
POLYCYSTIC  OVARIAN   SYNDROME  AND  ENDOMETRIAL  
CANCER 
Increased  androgen  production from  ovaries  are  converted to  
estrone.  There  is excess  amount  of  circulating  estrogen  and  
androgen.  Due  to   anovulation  the Production  of   progesterone  is  
decreased.  There  is unopposed  action  of  estrogen on endometrium 
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Polycystic  Ovarian   Syndrome  and   
Endometrial  Cancer 
 
          Ovary                                                                       adrenal 
 
         Estradiol                                                                   androgens 
                                                                            
                                                                                         estrones 
  
                                           Endometrium 
                                 
                                       Atypical hyperplasia 
 
                                             carcinoma 
Thus  women   with   PCOS,   have   increased  tendency to  get  
endometrial  cancer . They    also,   are  at  high   risk   of  developing   
breast  cancer   due  to  both   obesity  and  PCOS. 
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OTHER  ANDROGEN  EXCESS  DISORDERS 
PCOS is  the   diagnosis  of  exclusion,  so  all other  conditions  
presenting  with  chronic  anovulation  and  hyperandrogenism  should  
be  ruled  out. 
Thyroid  disorders 
Women  with  thyroid  disorders  have  menstrual  dysfunction , 
so   serum  thyroid  stimulating  hormone  should  be  done  to rule  out  
thyroid  disorders  in  all  anovulatory  women.  Both  hypothyroidism   
and  hyperthyroidism  patients  have  anovulatory  cycles. 
Hyperprolacinemia 
   Women  with  hyperprolactinemia     have   menstrual   
dysfunction. It  is  the most  common  cause  of  secondary  
amenorrhoea  ,  hence  women  with  menstrual  dysfunction  should  be  
tested  for  prolactin  levels.  
Androgen  secreting  tumors 
Both  ovarian  and  adrenal  tumors  can  be  excluded  by  
appropriate  history  and clinical  examination .  USG   will   diagnose  
most  of  the  ovarian  masses. Serum testosterone values more  than  
 
 
 
40 
 
150ng/dl  is  suggestive  of  malignancy.  Rapidly  progressing  
virilization  and  hirsuitism  also  suggests  androgen  producing  tumor. 
Cushing  syndrome 
Patients  with  cushing syndrome   have  all  clinical  features  
seen  in women  with PCOS.  Along  with  this , they  have  signs  and  
symptoms  suggestive  of  hypercortisolism   like  hypertension,  striae,  
atrophy  of  muscle  weakness.  The best screening  test  is  the   
Overnight  dexamethasone  suppression  test . 
Idiopathic  Hirsuitism 
Hirsuitism   will  be  accompanied  by  normal  ovulatory  
function.   It  results  due  to  peripheral   disorder  of  androgen  
metabolism.  The   condition  is  familial.  Androgens levels  are  not  
elevated  .  It  is  due  to  both  increase  in  the  number of  androgen  
receptors  and  also due  to  increased  sensitivity  of   the  receptors. 
Hair  follicles  show  increased  5alpha reductase  activity.  
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Cushing  Syndrome 
Figure   4 
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METABOLIC  DISTURBANCES : 
Most  of  the  women  with  PCOS  have  metabolic  
derangements  including   dyslipidemia,  insulin  resistance and  
Obesity.  They   are,  at  increased  for  developing  cardiovascular  
disease  and  type  2  diabetes mellitus.  Insulin  resistance  along   with  
obesity   increase  the  risk  of  developing  cardiovascular  disease. 
Many  women  with  PCOS  have  metabolic  syndrome. 
Metabolic  syndrome  is  also  called  as  metabolic  syndrome  X.  
Insulin  resistance  syndrome ,  syndrome  X  are  the names  given  to  it  
.  It  is  also   called  as  Revans  syndrome  ,named after  Gerald  Revan. 
It  is  due  to disruption  in  the  normal  process  of  energy  
utilization  and  storage  resulting  in  metabolic  abnormalities which  
include  dyslipidemia,  hypertension,  insulin  resistance,   high  fasting  
glucose,  obesity.  Atleast    three  of  the  five criteria  should  be 
present  to  diagnose  metabolic  syndrome. 
Women  with  PCOS  have  insulin  resistance,  obesity  and  
Hyperandrogenism   which  puts  them  under high  risk  for  developing   
metabolic  syndrome .  The  underlying  factors  for   metabolic  
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syndrome  are  genetics19,  physical  inactivity,  aging and  
proinflammatory  factors.    
There  are  different classifications  to  define   metabolic  
Syndrome.  The objective  of  all the  classification  is  to  provide  a  
simple  diagnostic  and  clinical tool  to  identify  people  who  have  
increased  of  developing  cardiovascular  disease  and    type  2  
diabetes mellitus. 
National  cholesterol  Education  Program  Adult  Treatment  
Panel(III)17  defines  metabolic  syndrome,  if  there   are  three  out  of  
the  following  five  features 
 1)   Waist  circumference  more  than  88cm  in females   
 2)  Hypertension  systolic  BP  more  than 130 mmHg  and diastolic  
BP  more  than  85 mmHg.     
3)  Triglycerides  more  than 150mg/dl 
4) High  Density  Lipoprotein (HDL)  less than  50mg/dl 
5) Fasting  blood  glucose  more  than  110mg/dl  
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WHO  World  Health  Organisation  defines  metabolic Syndrome  
as  that  ,    where  along  with  insulin  resistance     any  of  the  two  
following criteria  be  present. 
1) Hypertension  systolic  BP  more  than 140 mmHg  and 
Diastolic  BP  more  than  90 mmHg.     
2) Triglycerides  more  than 150mg/dl 
3) High  Density  Lipoprotein (HDL)  less than  50mg/dl 
4) Obesity  BMI  >  30kg/m2. or  waist  to  hip  ratio  >  0.85  
in  females 
5) Microalbuminuria   
International  Diabetes  Federation  defines  metabolic  syndrome  
as  central  obesity , waist  circumference  more  than  88cm  in  females  
and  more  than  104cm  in  males   plus  any  of  the  two  following   
criteria 
1) Hypertension  systolic  BP  more  than 130 mmHg  and 
 Diastolic  BP  more  than  85 mmHg 
2)  Triglycerides  more  than 150mg/dl 
3) High  Density  Lipoprotein (HDL)  less than  50mg/dl  
4) Fasting  blood  glucose  more  than  110mg/dl 
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NCEP  ATP III  guidelines  differ  from  that  of  WHO criteria 
.In  WHO  criteria  insulin  resistance is   calculated  , which  is  a  
cumbersome process  if  the  study  is  applied  to  large   population.  In  
NCEP  ATP  III  instead of  insulin  resistance  fastin  blood  glucose  is  
calculated  which  will give  a  better  idea  of  glucose metabolism  .  It  
is  of  more  help  in  predicting  the  progress  of  glucose  regulation  
abnormalitieslike  impaired   glucose  tolerance  and  diabetes mellitus. 
All  the factors  have  their  own  individual  risk  of  developing  
cardiovascular  disease.  The  combination  of  these  factors  further  
augment  the  chance of developing  coronary  heart   disease  and  
diabetes mellitus. 
   PCOS  women   have  insulin  resistance  .  Obesity  further  
accelerates  insulin  resistance .  In  women  with  PCOS  there  is  
increased  amount  of  triglycerides,   decreased  amount  of   HDL.  The  
amount  of  LDL  doesnot  vary  significantly  among     PCOS   
patients. 
Obesity  contributes to  hypertension,  high  serum  cholesterol  
like  triglycerides, low  HDL   and  impaired  glucose  tolerance. All 
these  are  risk  factors  for developing   coronary  heart   disease.  
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Obesity, by  itself   is an individual risk  factor  for developing  heart  
disease.    
The  final  point  in metabolic  syndrome  is  hypertension  .  It  is  
not  found  in  all  patients  and  requires  some  duration  of  time   to  
develop.  Women  with  Polycystic ovarian  syndrome  presenting  with  
insulin  resistance   develop  impaired  glucose  tolerance  and  also  type 
2  diabetes   mellitus  in  due  course  of  time.  
TREATMENT  OF  PCOS 
           Treatment  of  PCOS  includes  life  style  modification, which 
includes  diet  and  exercise, like moderate  exercises  for  30 minutes 
.losing weight upto 5% provides  good results. 
          Drugs includes estrogen progesterone contraceptives, metformin 
and    anti  androgens . 
          Estrogen  progesterone  contraceptives  pills  decreases  insulin  
sensitivity  in  women  with  PCOS  to  some  extent  but  long  term  
usage  may increase  the  risk  of  developing  type II diabetes  mellitus,  
cardiovascular  disease  in  women with PCOS  who  already  have  
insulin  resistance. 
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         Metformin  regularizes  menstrual  cycle and  is the  most  
important  treatment  in  young  women  presenting  with  anovulatory  
cycles  . Treatment  with  Metformin  decreases  the  risk  of  developing  
diabetes   and  heart  diseases. 
          The most appropriate  candidates  for treatment  with Metformin  
are  PCOS  women  with  impaired  glucose tolerance  and  patients  
with  evidence  of  insulin  resistance.  Clomiphen  citrate , Metformin,  
and  GnRH  agonists  form  the  main stay  of  treatment  in  PCOS 
patients  with  infertility.         
TREATMENT  OF HIRSUITISM 
   For  women  with  PCOS  presenting  with  acne,  hirsutuism,  
management options  include   cosmetic  measures,  medical  treatment  
and  surgical  treatment. 
Cosmetic  measures                                                                                                  
               These  are  useful   in  women  with  idiopathic  hirsuitism  and  
also  in  mild  hisruitism. Eflornithine  hydrochloride  cream  which  
inhibits ornithine  decarboxylase  enzyme  is used.    
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Medical management: 
          Combined  oral  contraceptive  pills  and  GnRH  agonists  
suppresses  pituitary  LH . COC pills also  suppress the  production  of 
ovarian testosterone. Medroxy progesterone acetate suppresses  pituitary 
LH, ovarian testosterone and also  inhibits  5 alpha  reductase .  
ketoconazole  blocks adrenal  and  ovarian  androgens . anti androgens  
like spironlactone, cyproterone  acetate ,  flutamide  inhibits  androgen  
binding  to  receptors. Finasteride  inhibits  5alpha reductase 
Surgical management : 
Clitoral  reduction  is  done  in  women  with  clitoromegaly.   
Androgen   secreting  tumours  are  managed  by  hysterectomy  and   
oophorectomy. Adrenal  adenomas  are  treated  by  adrenalectomy. 
INFERTILITY  : 
Women  ,  who   present  with  complaints  of  infertility  are  
treated  with  both  metformin  and  ovulation induction  drugs  like  
clomiphen  citrate,  aromatase  inhibitors  and  gonaadotropins. 
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Metformin   alone  or  in  combination  with  other  insulin  
senitizing  agents  improve the  menstrual  function  in most  women  
with  PCOS. 
Clopmiphen  citrate,   selective  estrogen  receptor  modulator has  
both  estrogen  agonist  and antagonist  activity.  Due to  negative  
feedback  of  estrogen there  is  rise  in  the  levels  of   GnRH ,  which  
in turn  causes  follicular  development. 
  Laparoscopic  ovarian  drilling   is  done  in women   who are  
resistant     to  clomiphen  and  gonadotropins .  It is  done restore  
ovulatory  dysfunction  .    Laparascopic  ovarian 28 drilling  is done   by    
electrocautery   and   also   by  laser  vaporization.  It is done  by  
puncturing  4  to  6  sites in  single  ovary.  Tubo  ovarian  surfaces  are  
avoided  to  decrease  the  risk  of  adhesions.  Adhesion  formation 
should  be  prevented , as it   will   affect  the escape  and  pickup of  
ovum.  It  causes destruction  of  ovarian  stroma   which  in  turn  
decreases   the  production  androgen   from ovaries. There  is  decrease   
in  the  levels of  both  testosterone  and  androstenedione.          
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TREATMENT  OF   OBESITY 
Treatment  of  obesity  includes  lifestyle therapy,  
pharmaceuticals  like metformin,  anti  obesity  drugs  and  bariatric  
surgery. Lifestyle28  therapy   remains  the  main  mode  of  treatment  of  
obesity.  Lifestyle therapy  includes  both   dietary component  exercise  
and   increased  physical  inactivity.   
Aerobic exercises   for  a  period  of  150 minutes  in  a  week  is 
recommended.  It  is  done in  divided  sessions.  
   Diet  therapy  includes   restriction  of  calories to about  500kcal. 
This  restriction  of  500 kcal/day   reduces  the weight  by  1pound per  
week29.   Diet low  in  carbohydrate is also  associated with    profound  
weight  loss.  
The  are  many  studies  in  women with  PCOS,   stating  the  use  
of metformin  is associated  with  weight loss.  There  is  a  meta  
analysis  that supports  the  use  of  metformin.The  only  drug  approved  
by  Food and  Drug  Administration  to  treat  obesity  is   Orlistat30.  
The  mechanism  of  action  of   Orlistat   is that  inhibits  the  activity  
of  intestinal  lipase  and  it  inhibits  the  absorption  of  fat. The  
amount  of weight  loss   after  one  year  use  is  5-7lbs23. Bariatric  
 
 
 
51 
 
surgery  is done  for  morbidly obese  patients  with  PCOS.  Studies  
have  proved  that long term  survival  is   superior  with  bariatric  
surgery  when  compared without  surgery31. 
TREATMENT  OF  METABOLIC SYNDROME   
The  main  objective    to  treat  metabolic   syndrome   is   to   
prevent  the  development   of  coronary   heart  disease,  and   type   2  
diabetes  mellitus.  Other risk  factors   contributing   to  the  
development   of  cardiovascular  disease  like smoking   should   be   
stopped.   Long  term  and  short  term  complications  can be  prevented   
by   appropriate   life   style   modifications.  These  include 
 Weight  loss  upto  10% . BMI  of  less  than  25kg/m2 should be  
maintained. 
 Moderate  physical exercise  of about  30 minutes             
 Diet  should   include  reduced  amount  of  salt, saturated fatty 
acids and  more  amount  of  polyunsaturated  fatty acids. 
 Each  individual  has   to be  treated  according  to  the  features  
they  have. 
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Treatment  of  insulin resistance 
     Diet  and  exercise  forms the  main  stay  of  treatment. In patients  
having  impaired  glucose tolerance  the  use  of   insulin sensitizing  
agents  like metformin  are  used.  Metformin  and other  insulin  
sensitizing agents  slow down  the  progress  of   both  insulin  resistance  
and impaired  glucose tolerance    to  diabetes  mellitus.  Acarbose  is  
also  used.  Patients  with  type  2  diabetes  mellitus  are   treated with  
insulin.  
Treatment of Lipid Abnormalities 
Lipid  disturbances  respond  well  to  exercise  and  weight  loss 
along  with  drug  therapy.  The main  aim  is  to treat  increased LDL  
levels.  Later  increased  triglycerides  and  reduced  HDL levels  are 
treated.  Statin  group   of  drugs along  with  niacin , and  fibrate  are 
used  to treat  lipid  abnormalities.Fibrates  decrease the LDL  levels  ,  
increase  HDL  levels  and also decrease TGL  levels 
Prevention  of   thromboembolic  disorders  
Patients  having  metabolic  syndrome are  more   prone  for  
thrombosis  due  to  disorders   in clotting  mechanism .   They  are  
treated  with  low dose aspirin  to   prevent  thrombotic  events. 
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Treatment  of  hypertension 
Hypertension  forms  an  important  risk  factor  for   developing  
metabolic syndrome. Maintaining  blood pressure at adequate levels 
improves  the  general  outcome.   
Angiotensin converting enzyme  inhibitors  and Angiotensin  
receptor blockers  are  used to treat  hypertension. 
Prevention 
Prevention  of  metabolic  syndrome  is  mainly  by adopting  
healthy  lifestyle  which  includes  balanced  diet,   moderate amount  of  
exercise  lasting   for  atleast  30 mts.  Women with  family  history of  
diabetes  or metabolic  syndrome  should  be  counselled  about  the  
complications  and  should  be  advised  to adopt  healthy  lifestyle  at  
the  earliest. 
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ACANTHOSIS   NIGRICANS 
Linear  velvety  pigmented  lesions   due  to  insulin  resistance. 
It appears  on  nape  of  neck  and  axilla. 
Figure 5 
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POLYCYSTIC   OVARIES 
Laparascopic  finding  of  polycystic  ovaries 
They  appear  as enlarged  and  pearly white  with  multiple  follicles 
Figure  6 
Laparascopic view  of    polycystic  ovaries 
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METHODOLOGY 
STUDY  DESIGN 
 Prospective , descriptive,  cross sectional  study   to   determine  
the  prevalence  of  metabolic   syndrome  in  patients  with  PCOS. 
 STUDY PLACE 
  Gynaecology  Outpatient  deparment,  Department of  Obstetrics 
and Gynaecology  Government  kilpauk  Medical  college  Hospital,  
Chennai  -10 
STUDY  POPULATION 
All  patients  who  satisfied   the  inclusion  and  exclusion  
criteria  below,  after  obtaining  consent  were  included  in  the  study  
and  those   in  exclusion  criteria  were  deleted from  the  study.    
INCLUSION  CRITERIA 
1. Women  in  the  age  group  18-45  years  
2. Patients presenting  with  menstrual  abnormalities 
Oligomenorrhoea (absence of  menses  for  35-182  days) and  
amenorrhoea(absence  of  menses  > 182  days) 
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3. Women  presenting  with  clinical  evidence  of  
hyperandrogenism  like  hirsuitism,  acne,  temporal  balding] 
4.   Women  with   ( acanthosis  nigricans ) 
5.   USG  evidence of  polycystic ovaries 
EXCLUSION CRITERIA 
1. Pregnancy 
2. Hyperprolactinemia 
SAMPLE  SIZE 
Sample  size  was  calculated   from  the  formula 
 N = z2p (1-q)/ E2 
N is  sample  size 
Z is  constant ,  point  corresponding  to  significant  level  of   5% z =  
1.96 
P  is  prevalence  of  metabolic  syndrome  (assumed) is  14%  p= .14  
Q = 1-P   = ( 1-.14)= .86 
E  is maximum  likely  error   5% 
N = 1.96*1.96*.14*.86/.05*.05 =  185 
Sample  size   is  185                                                                               
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ETHICAL  CLEARANCE  
Ethical  committee  clearance  was  obtained   from  the  Ethical  
committee ,  Kilpauk  medical  college.  All  the  patients  included  in  
the  study  were  informed  about  the  study  and  consent  was  obtained  
before eliciting  history and collecting  sample  for  lab  tests.                                     
 STUDY  PROCEDURES 
Patients   attending   gynaecology   department    in   the   age   
group  18-45  were    screened   for   menstrual  complaints.     Patients  
with  complaints  of   oligomenorhoea   and   amenorrhoea   were   
enrolled   in  the  study.  Detailed   history   was   taken   and   clinical   
examination   done  .  During  examination,  clinical   evidence  of   
hyperandrogenism    if   present   was   noted.   Hirsutism  was   
established   by   using   the    modified  Ferriman–Gallwey   score. 
Transvaginal   ultrasonography   was    systematically  performed   
in   logic mindray,  using the 7.5 MH z  transvaginal   probe.  Ovarian   
volume measurements   were   carried  out   by  using  three  
perpendicular   dimensions and   applying   the   equation   for   the    
volume   of     an   ellipsoid .  Antral follicles   were   measured   in   
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three   dimensions   and   those   with   a   mean diameter  of   2–9 mm 
counted. 
 Other disorders like  hypothyroid,  and  hyperprolactinemia   
causing   menstrual  abnormalities  were ruled  out  by  measuring serum  
TSH  levels  and prolactin  levels.  Patients who  satisfied Rotterdam  
criteria  of  PCOS  were  taken  as  study  participants.  
Rotterdam  criteria  for  PCOS  is as  follows ,  atleast   two   of   
the  three  major  criteria  should  be  present. 
1)   Oligomenorrhoea  
                      2)  Clinical  or  biochemical    hyperandrogenism 
                      3)  Polycystic  ovaries  (USG) , excluding   other  
androgen   excess         
Clinical  Measurements  
Weight  of  the participants  was  measured  using  the Secca 
weighing  scale. Calibration  was done  every  morning  before starting  
the  work  using  a  standard  weight.  Weight was taken  without  shoes  
and  in  light  clothing. Reading  was measured  to  the  nearest  0.5 
kilograms. 
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Height  assessment  was  done  using  a  height  measuring  rod 
without  shoes  and  recorded  to  the  nearest 0.5 centimeters. 
BMI  for  each  person  was  calculated  by  dividing  weight 
(kilograms)  with  height  squared(meter).  
BMI  of  30kg/m2  and  over,  was  taken  as obesity. 
  Waist  circumference  was  also  taken  using  a  non-stretchable  
tape  measure   at  level  of  the  uppermost  edge  of  the  hip bone  on  a  
light  clothed  abdomen  with  the  tape  parallel  to the  ground  and  
recorded  to  the  nearest  0.5 centimeters.   The   measurement   above  
88cm  was  considered   as  central obesity.  This   was  according   to  
the  IDF  &  NCEP  ATP III criteria 
Blood  Pressure  Measurements:  
Blood pressure was taken from the arm (brachial artery)    
from  all   patients   in   the   first   encounter by using digital 
sphygmomanometer. 
Blood pressure measurement was done in a sitting position with 
the arm supported andrepeated after 5 minutes; the average of the two 
measurements was taken as a blood pressure. 
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The systolic pressure of above or equal to140mmHg and diastolic 
pressure above or equal to 90mmHg was regarded as a high blood 
pressure.  
Those who found to have high BP were referred to a physician for 
further evaluation and possible   treatment 
After  an  overnight  fasting,  blood  samples  for  high  density 
lipoproteins (good cholesterol),  serum  triglycerides  and  blood glucose  
was  collected.  Five  millilitres  of  venous  blood  was  taken  from  the  
antecubital  fossa  and  placed  in  empty sterile  tubes.  The  samples  
were  transported  to  the laboratory. 
DIAGNOSTIC  CRITERIA 
 In  this  study  National   Cholesterol  Education  Programme 
ATP  III  criteria  of  metabolic  syndrome  was   used.  According  to  
this  criteria  atleast  three  of  the  following  five  criteria  should  be  
present 
1)  Waist  circumference  more  than  88cm  in females  and   
   more than  104cm  in  males. 
2)  Hypertension  systolic  BP  more  than 130 mmHg  and 
Diastolic  BP  more  than  85 mmHg.     
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3)  Triglycerides  more  than 150mg/dl 
4) High  Density  Lipoprotein (HDL)  less than  50mg/dl 
5) Fasting  blood  glucose  more  than  110mg/dl 
Patients   with  high  blood  pressure  were   referred  to  
physician.  Patients with  increased  fasting  blood  glucose,  high   TGL,   
low   HDL  levels  were  advised to  repeat  the  blood investigations  
and  patients  with  persistence  high  values   were  referred  to 
physician. 
DATA  ANALYSIS 
Collected  data  was  entered   into  computer   statistical  
program.  Analysis  was  done using  SPSS  version  15.  Comparison  
of  variables  was  done  using   chi square  test.   P  value  of  less  than  
.05  was  taken  as  statistical significance. 
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AGE GROUP  AND METABOLIC SYNDROME (MS) 
The  association  between  age  and  prevalence  of  metabolic 
syndrome  was  evaluated.  Patients   were  divided  into  four  age 
groups.  
Table 1     AGE GROUP  AND METABOLIC SYNDROME (MS)   
 
Age    group 
Metabolic    syndrome 
Present Absent Total 
         Count 
1         %within  MS                         
        Total  %   
     0 
    0 
     0 
11 
6.7% 
      5.7% 
    11 
    6.7% 
     5.7% 
        Count 
2         %within  MS                         
                    Total  %   
     6 
    20.7% 
     3.1% 
     57 
     34.5% 
     29.4% 
     63 
     32.5% 
     32.5% 
        Count 
3         %within  MS                         
                    Total  %  
     19 
    65.5% 
      9.8 % 
      87 
      52.7% 
     44.8% 
     106 
     54.6% 
      54.6% 
        Count 
4         %within  MS                         
                    Total  %   
     4 
    13.8% 
       2.1% 
     10 
      6.1% 
      5.2 % 
      14 
      7.2 % 
      7.3% 
TOTAL   COUNT 
               % within  MS     
      29 
    100% 
     165 
     100% 
      194 
      100% 
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Age  of  20  -25  were  in  the  first  group, in  second group 
patients  were   in  the  age group  26-30,third  group  had patients 
between  age  31-35 , fourth  group  had  patients  in  the  age group  36-
40years. 
Majority  of  patients , about  107  of  them  were in  the  age  
group  of  31-35 years.  About  63 patients  fell  in  the age  group  of  
26-30years. 14  were  in  the  age  group  36-40 years  and  11  were  in  
the  age  group  21-25. 
Among  107  patients,  19  had  metabolic  syndrome.  Out  of  63  
patients,  6  had  metabolic  syndrome.  Out  of  14  patients  11  had 
metabolic  syndrome. The  age  group  analysis  was  made  using  chi -
square test. 
P  value  was  found  to  be  0.103   
The  association  was  not  found  to  be  statistically  significant. 
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Figure -  7 
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 Polycystic  ovaries and Metabolic Syndrome 
Among  194  patients  185 patients  had  USG  evidence of 
polycystic ovaries.  Out of this 20  patients  had  metabolic  syndrome. 
Polycystic ovaries  were   absent  in  9 patients , but  all  the 9  patients  
had  metabolic  syndrome. 
TABLE  2 
Polycystic  ovaries and  Metabolic Syndrome 
Polycystic  ovaries(USG) 
Metabolic  Syndrome 
Absent Present Total 
        Count 
Absent        %within  MS                         
                    Total  %  
0 
0
0 
9 
31% 
4.6% 
9 
4.6% 
4.6% 
        Count 
Present        %within  MS                         
                    Total  %   
165 
100%
85.1% 
20 
69% 
10.3% 
185 
95.4% 
95.4% 
TOTAL     COUNT 
       % within  MS  
        Total  %    
165 
100% 
85.1% 
29 
100% 
14.9% 
194 
100% 
100% 
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Relationship  between  the  usg  evidence of polycystic  ovaries and  metabolic  
syndrome  was evaluated  using  chisquare  test  and Fisher’s  exact  test  .  The  
p  value  was found  to  be  <.05 . 
The  relationship  was  found to  be  statistically  significant 
TABLE 3 
Chi-Square Tests 
 
 
Value Df 
Asymp. Sig. 
(2-sided) 
Exact 
 Sig. (2-
sided) 
Exact 
Sig.   
(1-sided) 
Pearson Chi-Square 53.698a 1 .000   
Continuity Correctionb 46.912 1 .000   
Likelihood Ratio 36.923 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear 
Association 
53.421 1 .000 
  
N of Valid Cases 194     
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Figure – 8 
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HIRSUITISM AND METABOLIC SYNDROME. 
Hirsuitism  was  present  in  101  patients  and  absent  in 93 
patients.  Among  101  patients  28 patients  had  metabolic syndrome.  
In 93 patients only  1  patient  had metabolic  syndrome.  
TABLE 4 
Hirsuitism  and  Metabolic Syndrome 
Hirsuitism 
Metabolic  Syndrome 
Absent Present Total 
        Count 
Absent        %within  MS                         
                    Total  %  
92 
55.8% 
47.4% 
1 
3.4% 
.5% 
93 
47.9% 
47.9% 
        Count 
Present        %within  MS                         
                    Total  %   
73 
44.2% 
37.6% 
28 
96.6% 
14.4% 
101 
52.1% 
52.1% 
TOTAL     COUNT 
       % within  MS     
       % of  Total 
  165 
100% 
85.1% 
29 
100% 
100% 
194 
100% 
100% 
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Relationship  between hyperandrogenism  and  metabolic syndrome  
using   hirsuitism  was evaluated  by chi-square test. 
P-value  was  found  to be  less than  .05.   
The  association  was  found  to  be statistically  significant  . 
TABLE 5 
Chi-Square Tests 
 
Value df 
Asymp. 
Sig.  
(2-sided) 
Exact  
Sig. (2-
sided) 
Exact  
Sig.  
(1-sided) 
Pearson Chi-Square 27.042a 1 .000   
Continuity Correctionb 24.987 1 .000   
Likelihood Ratio 33.366 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear 
Association 
26.903 1 .000 
  
N of Valid Cases 194     
 
  
 
 
 
71 
 
Figure -  9 
Hirsuitism  and  Metabolic  Syndrome 
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  ACANTHOSIS NIGRICANS AND METABOLIC SYNDROME 
Among 194  patients , acanthosis  nigricans  which is  an  
evidence  of  insulin  resistance  was  present  in  14  patients.   Out  of  
14,  ten patients  had  metabolic  syndrome. 
TABLE  6 
Acanthosis   Nigricans  and   Metabolic  Syndrome 
 
Acanthosis  Nigricans 
Metabolic  Syndrome 
Absent Present Total 
        Count 
Absent        %within  MS                         
                    Total  %  
161 
97.6% 
83% 
19 
65.5% 
9.8% 
180 
92.8% 
92.8% 
        Count 
Present        %within  MS                         
                    Total  %   
4 
2.4% 
2.1% 
10 
34.5% 
5.2% 
14 
7.2% 
7.2% 
TOTAL     COUNT 
       % within  MS     
       % of  Total 
  165 
100% 
100% 
29 
100% 
100% 
194 
100% 
100% 
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The  association  between  acanthosis  nigricans  and  
metabolicsyndrome  was  evaluated  using   chisquare  test. 
p- value  was  found  to  be  <   .05.   The  relationship  was  to  be  
statistically  significant. 
 
TABLE 7 
Chi-Square Tests 
 
Value Df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 37.859a 1 .000   
Continuity Correctionb 33.223 1 .000   
Likelihood Ratio 25.549 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear 
Association 
37.664 1 .000 
  
N of Valid Cases 194     
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Figure 10 
Acanthosis  Nigricans   and  Metabolic  Syndrome 
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PCOS  AND  METABOLIC  SYNDROME 
Patients  with  polycystic  ovarian  syndrome were divided  into  
three  groups  .  The  first  group  had  patients  who  satisfied  all three  
criteria of  Rotterdam (ie)  1.hyperandrogenism,  2.anovulation  3. usg  
evidence  of  polycystic  ovaries . 
TABLE  8 
PCOS  and  Metabolic  Syndrome 
 
Age    group 
Metabolic    syndrome 
Present Absent Total 
         Count 
5         %within  MS                         
        Total  %   
     0 
    0 
     0 
11 
6.7% 
      5.7% 
    11 
    6.7% 
     5.7% 
        Count 
6         %within  MS                         
                    Total  %   
     6 
    20.7% 
     3.1% 
     57 
     34.5% 
     29.4% 
     63 
     32.5% 
     32.5% 
        Count 
7         %within  MS                         
                    Total  %  
     19 
    65.5% 
      9.8 % 
      87 
      52.7% 
     44.8% 
     106 
     54.6% 
      54.6% 
TOTAL   COUNT 
               % within  MS     
      29 
    100% 
     165 
     100% 
      194 
      100% 
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Second  group had  patients  with  anovulation  and  usg  evidence  
of  polycystic  ovaries.Third  group  constituted  patients  with  
anovulation and  hyperandrogenism.  Number  of  patients   with  
metabolic  syndrome  in  first , second and  third  group  were   20,  1,  
and 8   respectively. 
The  risk  of  developing  metabolic  syndrome  between the three  
groups  were  assesed  using  chisquare  test .  There  was  difference  in  
risk  between  the three  groups  .  The  difference  was  found to  be  
stastistically  significant.  From the   above  analysis  it  can  be  
concluded  that  clinical  hyperandrogenism  is  important  risk  factor  in  
developing metabolic  syndrome.It  can  also  be  concluded  that  all 
patients  with usg evidence of  polycystic ovaries  donot  necessarily  
develop, metabolic syndrome. 
TABLE 9 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 62.741a 2 .000 
Likelihood Ratio 55.782 2 .000 
Linear-by-Linear Association .061 1 .805 
N of Valid Cases 194   
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Figure  11 
PCOS  and  Metabolic  Syndrome 
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Relationship  between patients  with  and without  metabolic syndrome  
was  analysed.  It  was analysed  using  independent  t  test.   
Table   10   Group Statistics 
 
MS N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Age 1 29 32.41 2.872 .533 
0 165 30.66 3.652 .284 
BMI 1 29 24.28 1.099 .204 
0 164 22.40 1.849 .144 
Waist 
circumference 
1 29 93.03 3.311 .615 
0 165 87.02 5.534 .431 
Sys BP 1 29 130.52 15.256 2.833 
0 165 109.76 7.647 .595 
Dias BP 1 29 83.10 10.037 1.864 
0 165 70.85 5.988 .466 
FBS 1 29 92.69 18.517 3.438 
0 165 83.32 7.414 .577 
TGL 1 28 147.11 10.874 2.055 
0 165 138.75 7.371 .574 
HDL 1 29 47.07 3.741 .695 
0 165 54.79 2.869 .223 
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The  variables  taken for  analysis  were  age group, systolic  BP, 
diastolic  BP,  HDL,  TGL,  waist circumference, BMI and  fasting  
blood  glucose  level. 
Except  age group,  all other  variables  contributed   to  the   
difference  between patients  with  and  without  metabolic syndrome  
and they were  statistically  significant . 
Of all  these  variables,  waist  circumference  had  a  strong  
correlation  towards metabolic syndrome. All patients  with  metabolic  
syndrome  had  increased waist  circumference.  
p- value was  found  to  be  less  than  .05   for  all  the variables  
and  the  co-relation  was  found  to be  statistically  significant 
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Table   11 
Independent Samples Test 
 
 
 t-test for Equality of Means 
   
  
df Sig. (2-tailed) 
Mean 
Difference 
AGE Equal variances assumed 192 .015 1.753 
Equal variances not assumed 45.539 .006 1.753 
BMI Equal variances assumed 191 .000 1.873 
Equal variances not assumed 60.481 .000 1.873 
WAIST 
CIRCUMFERENCE 
Equal variances assumed 192 .000 6.016 
Equal variances not assumed 59.787 .000 6.016 
SYS BP Equal variances assumed 192 .000 20.760 
Equal variances not assumed 30.517 .000 20.760 
DIAS BP Equal variances assumed 192 .000 12.255 
Equal variances not assumed 31.592 .000 12.255 
FBS Equal variances assumed 192 .000 9.375 
Equal variances not assumed 29.596 .012 9.375 
TGL Equal variances assumed 191 .000 8.362 
Equal variances not assumed 31.343 .000 8.362 
HDL Equal variances assumed 192 .000 -7.719 
Equal variances not assumed 34.024 .000 -7.719 
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Figure  12 
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Individual  risk  factors   of  each  component   for  metabolic syndrome  
is as follows 
 Hypertension   11.7% 
 High  FBS   12% 
 Increased waist circumference  36% 
 Low  HDL    17.6% 
  High  TGL  8.8% 
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DISCUSSION 
The main  objective  of this study  is   to  determine  the  
prevalence of  metabolic  syndrome  in  women   diagnosed  as PCOS 
according to the Rotterdam criteria. The main findings are that the 
overall prevalence of syndrome is  16.1%. Moreover, within this 
anovulatory cohort, the hyperandrogenic PCOS phenotype is associated 
with the highest risk of metabolic abnormalities. 
  In comparison to other studies with similarly diagnosed PCOS 
women, the prevalence of metabolic abnormalities in our study group is 
lower.prevalence is  35–44% in American (Shroff et al., 2007) and 
Australian anovulatory PCOS women (Cussons et al., 2008), 
comparable to the 16% reported in 
Taiwanese anovulatory PCOS women (Chen et al., 2006), but 
higher than the 8.2% reported in Southern Italian women with 
anovulatory PCOS (Carmina et al., 2006). 
The   prevalence  of  risk   factors  for  metabolic  syndrome in 
this study showed that obesity was  the  most important. 
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Low level of HDL-C and impaired fasting glucose were the most 
frequent (17.6% and 11.4% respectively) components of metabolic 
syndrome. This could make the  population  to  have  greater odds of 
having cardiovascular disease and type 2 diabetes . 
  Systemic hypertension was also found to be one of the most 
components of MS by 11.7%. The findings were similar in studies done 
in Nigeria  and Cameroon.  
Elevated level of serum triglyceride was frequent in 8.8% 
subjects. This was contrary to  what  had  been  shown in a study done 
in Sub Saharan Africa where elevated triglyceride was the  least  risk  
factor. 
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SUMMARY  AND  CONCLUSION 
This   prospective  cross  sectional  descriptive  study evaluated  
194  patients with  PCOS  by  both  clinical  and  labarotory  tests, 
following  the inclusion  and  exclusion  criteria at  Government  kilpauk  
Medical  college 
In  this  prospective  study  of  194  patients  with  PCOS, 
according  to Rotterdam  criteria  the  prevalence   of  metabolic  
syndrome  was  found  to be  16.1%. 
In this  study patients  with PCOS  were  classified  into  three 
groups.   
First group had patients  who satisfied  all  three criteria  like  
menstrual abnormalities,  hyperandrogenism,  and USG evidence  of  
Polycystic ovaries .  
 Second  group  were patients  with menstrual  irregularities  and  
usg  evidence  of  polycystic ovaries.    
Third  group  constituted  women  with  hyperandrogenism  and  
menstrual  irregularities. 
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Prevalence  of metabolic   syndrome  in  each  group are  as  
follows. 
Prevalence in first group 21% 
Prevalence in second group  1% 
Prevalence   in   third  group   is  100% 
Out  of  194 patients  29  patients  had  metabolic syndrome. 
Out   of  29  patients,  I  patient  met  all  five  criterias. 
10  out  of  29 patients  met  4  criterias. 
18  patients  met 3  criterias. 
Odds  ratio    for  acanthosi  nigricans with reference to metabolic 
syndrome  was found  to be 21. 
 Odds  ratio    for  hirsuitism  with  reference  to  metabolic 
syndrome  was  found  to be 35 
Hyperandrogenism  is  important  risk  factor  in  developing  
metabolic  syndrome. 
Individual  risk  factors   of  each  component   for  metabolic 
syndrome  isas follows 
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 Hypertension   11.7% 
 FBS   12% 
 Increased waist circumference 36% 
 HDL    17.6% 
 TGL  8.8% 
All  patients  with  metabolic  syndrome  had  increased  waist  
circumference. 
Hence  all  PCOS  women with  clinical  hyperandrogenism and  
increased  waist  circumference   should  be  screened  for  metabolic  
syndrome. 
Women  at  risk  of  developing  metabolic  syndrome  should  be 
adviced  about lifestyle  modifications .  
Life style  therapy  forms  the  main  stay   of  treatment  for  both  
PCOS  and  metabolic  syndrome. 
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PROFORMA 
 Name    : 
 Age     : 
 Occupation   : 
 Address    : 
 OP  No.   : 
 Age of  menarche  : 
 Married    : 
 Menstrual history   : Cycle 
     Duration of flow 
     Amount 
     Pain   
 Family  History  of  TB/ DM / HT : Yes / No  
 General Examination  :  
 Height   
 Weight 
 BMI 
 Breasts  
 Thyroid   
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 Hirsuitism    
 Acne  
 Acanthosis  Nigricans 
 BP 
 Waist  circumference  
 External  genitalita     
 Speculum  examination : 
 Bimanual  pelvic  Examination 
 Uterus  -  Normal  /  Enlarged / Atrophic  / Absent  
Position  - AV / RV  
 Investigations  
 Fasting  blood  sugar 
 High  Density  Lipoprotein  
 Triglycerides  
 Serum TSH 
 Serum Prolactin  
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                                 MASTER CHART 
S.NO NAME AGE 
MENST   
CYCLES PCO(USG) H AN BMI WC SBP DBP FBS 
1 JAYALAKSHMI 28 Oligo 1 0 0 23 83 110 70 88 
2 SATHYA 35 Oligo 1 0 0 23 85 110 60 79 
3 SIJIMA 31 Oligo 1 1 1 24 90 140 90 114 
4 JAYALAKSHMI 32 Oligo 1 1 0 24 91 120 80 74 
5 RAMITHA 33 Oligo 1 1 0 25 94 140 90 77 
6 AMUDHA 34 Oligo 1 1 0 25 95 140 90 79 
7 SRIDEVI 33 Oligo 1 0 0 24 88 100 60 82 
8 KANCHANA 32 Oligo 1 0 0 23 86 100 70 88 
9 SRIDEVI 27 Oligo 1 0 0 23 83 110 70 89 
10 TAMILARASI 26 Oligo 1 0 0 22 82 120 80 90 
11 THARAMANI 24 Ameno 1 0 0 22 80 110 70 74 
12 ARUL 34 Oligo 1 0 0 22 81 120 70 79 
13 MAGESHWARI 33 Oligo 1 0 0 21 79 120 80 80 
14 KALPANA 32 Oligo 1 1 1 26 98 110 60 120 
15 SELVI 27 Oligo 1 0 0 19 75 110 60 70 
16 JANSIRANI 24 Oligo 1 0 0 20 80 100 60 79 
17 YAMINI 28 Oligo 0 1 0 25 93 140 90 82 
18 INDRA 29 Oligo 1 0 0 19 77 100 60 60 
19 SUMATHY 32 Oligo 1 0 0 19 78 120 80 84 
20 PREMALAKSHMI 26 Oligo 1 0 0 19 79 110 70 88 
21 AMBIKA 34 Oligo 1 0 0 19 80 110 70 89 
22 LALITHA 35 Oligo 1 0 0 20 82 100 60 85 
23 MAHESHWARI 32 Oligo 1 0 0 21 83 120 80 90 
24 TAMILSELVI 36 Oligo 1 0 1 24 89 110 70 119 
25 VAISHNAVI 32 Oligo 1 0 0 24 86 120 80 79 
26 SELVI 31 Oligo 1 0 0 25 88 110 70 83 
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27 GOVINDAMMAL 32 Oligo 1 0 0 25 89 120 70 85 
28 PAVITHRA 28 Oligo 1 1 1 26 90 100 60 112 
29 SELVI 27 Oligo 1 1 0 25 94 100 70 85 
30 SHANTHI 33 Oligo 1 1 0 25 95 120 80 83 
31 KASTHURI 35 Oligo 1 1 0 24 90 140 90 86 
32 REVATHY 36 Oligo 1 1 0 24 89 120 80 88 
33 SUSEELA 37 Oligo 0 1 0 24 95 150 90 89 
34 RANI 37 Oligo 1 0 0 23 84 110 70 90 
35 VIJAYA 34 Oligo 1 0 0 19 77 120 80 85 
36 MEENA 34 Oligo 1 1 0 26 98 110 80 87 
37 RATHA 32 Oligo 1 1 0 26 99 120 70 83 
38 LATHA 32 Ameno 1 1 0 24 91 100 70 82 
39 KALAIVANI 28 Oligo 1 1 0 23 87 100 60 85 
40 BANU 26 Oligo 1 0 0 23 86 100 70 70 
41 FOWSIA 26 Oligo 1 1 0 24 89 120 80 77 
42 NALINI 22 Oligo 1 0 0 22 84 100 70 74 
43 SARASWATHY 22 Oligo 1 0 0 23 85 120 70 75 
44 RATHI 35 Oligo 0 1 0 25 93 150 90 72 
45 MOHANA 28 Oligo 1 0 0 22 83 100 70 80 
46 DEVIPRIYA 30 Oligo 1 0 0 23 87 100 70 90 
47 SAKUNTHALA 31 Oligo 1 1 0 23 88 120 80 89 
48 ANUSUYA 34 Oligo 1 1 0 24 89 120 80 83 
49 ANANDHI 33 Oligo 1 0 0 23 86 100 60 88 
50 SAMYUKTHA 32 Oligo 1 0 0 23 87 100 60 87 
51 HEMAMALINI 32 Oligo 1 1 0 24 89 120 60 81 
52 PARVATHY 34 Ameno 1 1 0 24 90 100 60 75 
53 USHA 35 Oligo 1 1 0 24 91 100 60 72 
54 SUBASHINI 36 Oligo 1 1 0 24 92 100 60 79 
55 KANCHANA 34 Oligo 1 1 0 25 94 140 90 81 
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56 SUBHA 33 Oligo 1 1 0 26 95 110 70 86 
57 SAVITHIRI 32 Oligo 1 1 0 25 92 110 70 82 
58 CHITRA 31 Oligo 1 1 0 24 90 120 80 89 
59 SHAMMEMMA 30 Oligo 1 0 0 22 81 100 60 90 
60 MEENATCHI 27 Oligo 1 1 0 24 89 100 60 89 
61 GOMATHY 26 Oligo 1 1 0 23 88 110 60 73 
62 DEEPA 29 Oligo 0 1 0 24 89 140 90 72 
63 GOWRI 30 Oligo 1 0 0 23 86 110 60 77 
64 HEMALATHA 31 Oligo 1 1 0 23 88 110 70 79 
65 VISALAKSHI 32 Oligo 1 0 0 22 82 110 70 80 
66 KANNIYAMMAL 35 Oligo 1 1 0 23 89 100 70 73 
67 SHANTHA 33 Oligo 1 1 0 23 90 110 70 75 
68 RAMYA 32 Oligo 1 1 0 24 85 100 70 90 
69 MANJULA 30 Oligo 1 0 0 23 83 120 80 82 
70 RAMALAKSHMI 34 Oligo 1 0 0 23 87 110 80 87 
71 PAULIYA 33 Oligo 1 0 0 19 82 120 80 89 
72 VASUKI 32 Oligo 1 1 0 24 90 100 70 90 
73 DEVIPRIYA 30 Oligo 1 1 1 24 91 110 70 110 
74 ANITHA 31 Oligo 1 1 0 24 93 100 70 83 
75 SULOCHANA 29 Oligo 1 1 0 23 99 110 70 82 
76 MAHALAXMI 31 Oligo 1 1 0 25 94 110 70 85 
77 ANJANA 30 Oligo 1 1 0 24 96 110 70 88 
78 VIDHYA 34 Oligo 1 1 0 24 90 110 70 89 
79 MEGALA 32 Oligo 1 0 0 19 77 110 70 90 
80 SARRAL 33 Oligo 0 1 1 25 96 110 70 116 
81 TAMILSELVI 26 Ameno 1 0 0 19 79 110 70 82 
82 BARATHI 26 Oligo 1 0 0 21 82 110 70 81 
83 NIRMALA 27 Oligo 1 0 0   86 100 70 80 
84 JAYA  28 Oligo 1 0 0 22 84 100 70 85 
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85 AKILA 25 Oligo 1 0 0 23 88 120 70 89 
86 LAKSHMI 27 Oligo 1 1 0 23 89 110 70 90 
87 KARPAGAM 21 Oligo 1 1 0 24 90 110 70 84 
88 VEENA 29 Oligo 1 1 0 24 91 120 70 82 
89 SHANTHI 26 Oligo 1 1 0 24 94 110 70 85 
90 PRIYA 29 Oligo 1 1 0 24 95 100 70 80 
91 HEMA 30 Oligo 1 1 0 26 97 110 70 82 
92 DEVIKALA 31 Oligo 1 1 0 25 90 100 70 84 
93 NATHIYA 32 Oligo 0 1 1 24 94 100 70 123 
94 SHEELA 32 Oligo 1 1 0 25 96 100 70 86 
95 BABY 34 Oligo 1 1 0 23 90 100 70 89 
96 VASANTHI 36 Oligo 1 1 0 24 91 110 70 85 
97 PARIMALA 35 Oligo 1 1 0 24 92 110 70 82 
98 JOTHY 26 Ameno 1 1 0 23 94 110 70 80 
99 LAKSHMI 23 Oligo 1 0 0 22 89 110 70 77 
100 ARCHANA 34 Oligo 1 1 0 22 88 120 70 74 
101 BARANI 32 Oligo 1 0 0 22 87 110 70 72 
102 MUBEENA 33 Oligo 1 0 0 22 85 110 70 70 
103 MALAR 35 Oligo 1 0 0 22 87 110 70 76 
104 DHANALAKSHMI 37 Oligo 1 1 0 23 89 110 70 79 
105 JEEVA 30 Oligo 1 1 0 24 90 110 70 74 
106 JEYAKALA 31 Oligo 1 1 0 24 92 120 80 77 
107 DAISY 30 Oligo 1 1 0 23 93 110 70 79 
108 PADMA 31 Oligo 1 1 0 24 95 110 70 80 
109 VANITHA 34 Oligo 1 1 1 26 97 140 90 112 
110 REGINA 33 Oligo 1 1 0 24 94 110 80 85 
111 ANNIE 32 Oligo 1 1 0 24 94 110 70 88 
112 ANANDHI 35 Oligo 1 1 0 24 95 110 60 82 
113 MARIAMMAL 37 Oligo 0 1 1 23 91 120 80 119 
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114 KOWSALYA 39 Oligo 1 1 1 23 92 110 70 119 
115 JEYANTHI 32 Oligo 1 1 0 23 90 120 80 70 
116 PRABHAVATHY 33 Oligo 1 1 0 24 94 140 90 75 
117 KAMATCHI 35 Oligo 1 1 0 24 92 140 90 79 
118 VIJI 34 Oligo 1 1 0 23 94 140 90 84 
119 SUCHITRA 31 Oligo 1 1 0 23 95 135 90 83 
120 GNANAPRIYA 25 Oligo 1 1 0 22 92 120 80 87 
121 KEERTHIGA 29 Oligo 1 1 0 24 95 110 70 89 
122 GAYATHRI 31 Oligo 1 1 0 24 93 150 90 90 
123 MALATHI 30 Oligo 1 1 0 24 92 110 70 79 
124 PREMALAKSHMI 31 Oligo 1 0 0 19 87 100 60 74 
125 RENUGA 33 Oligo 1 0 0 20 83 120 70 80 
126 RAJI 31 Oligo 1 0 0 22 87 110 70 81 
127 KAVITHA 32 Oligo 1 1 0 22 89 110 70 85 
128 FARIDHA 33 Oligo 1 0 0 22 80 120 80 86 
129 FATHIMA 34 Oligo 1 0 0 20 79 110 70 90 
130 PRIYA 33 Oligo 1 0 0 20 77 120 80 80 
131 SARASWATHY 34 Oligo 1 0 0 21 80 120 80 90 
132 SHEEBA 31 Oligo 0 1 1 26 99 120 80 114 
133 MENAKA 32 Oligo 1 0 0 23 86 120 80 85 
134 TAMILSELVI 30 Oligo 1 1 0 23 88 120 60 88 
135 SARALA 36 Oligo 1 1 0 24 89 140 90 82 
136 DHATCHAYANI 35 Oligo 1 0 0 24 87 120 80 89 
137 DEEPA 32 Ameno 1 0 0 22 83 120 80 80 
138 DAISY 33 Oligo 1 1 0 23 89 140 90 79 
139 KALI 36 Oligo 1 0 0 23 87 110 80 80 
140 ILAVARASI 29 Oligo 1 0 0 23 86 120 80 85 
141 MALINI 25 Oligo 1 1 0 23 88 100 60 87 
142 JEYEPRABHA 24 Oligo 1 0 0 20 84 100 70 77 
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143 REVATHI 22 Oligo 1 0 0 20 85 100 60 76 
144 ISHWARYA 27 Ameno 1 0 0 22 86 120 70 78 
145 HARINI 27 Oligo 1 1 0 22 88 120 80 70 
146 MANJULA 29 Oligo 1 1 0 23 89 140 90 74 
147 PARVATHY 30 Oligo 1 0 0 23 90 110 70 80 
148 VENI 31 Oligo 1 1 0 23 92 110 70 85 
149 GANGADEVI 32 Oligo 1 1 0 23 90 100 70 83 
150 ARTHI 33 Oligo 1 1 0 27 112 100 60 112 
151 ASMA 34 Oligo 1 1 0 25 98 100 70 89 
152 CHANDRA 35 Oligo 1 1 0 24 89 110 70 90 
153 KEERTHIGA 37 Oligo 1 0 0 23 87 110 70 72 
154 ARCHANA 36 Oligo 1 1 0 23 88 120 70 112 
155 RATHA 33 Oligo 1 0 0 20 83 120 70 77 
156 POOVITHA 32 Oligo 0 1 1 26 102 120 70 119 
157 POORANI 31 Oligo 1 0 0 22 85 120 80 80 
158 DEVAKI 30 Oligo 1 0 0 21 87 100 70 84 
159 RANI 34 Oligo 1 1 0 23 90 110 70 88 
160 ANNAMAL 35 Oligo 1 1 0 23 92 100 70 89 
161 ARULARASI 34 Oligo 1 0 0 19 78 120 70 90 
162 BANU 33 Oligo 1 1 0 21 90 110 80 76 
163 NITHYA 32 Oligo 1 1 0 21 91 100 70 74 
164 VANITHA 31 Oligo 1 1 0 22 94 100 80 79 
165 ARUNA 29 Oligo 1 1 0 22 89 120 70 90 
166 UMA 27 Oligo 1 0 0 22 87 110 70 85 
167 NEERAJA 29 Oligo 1 0 0 21 86 110 80 83 
168 KALA 27 Oligo 1 0 0 20 85 110 70 82 
169 GEETHA 26 Oligo 1 0 0 19 79 120 70 89 
170 SUBHA 24 Oligo 1 0 0 19 78 100 70 90 
171 SANGEETHA 31 Oligo 1 0 0 20 80 110 70 74 
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172 MEENA 34 Oligo 1 0 0 20 82 110 70 78 
173 THENMOZHI 26 Oligo 1 0 0 19 83 110 70 75 
174 KARTHIGA 27 Oligo 1 0 0 18 76 110 70 80 
175 KAVERI 23 Oligo 1 0 0 20 80 100 70 82 
176 HAJEERA 25 Oligo 1 0 0 21 84 100 70 83 
177 RAZIYA 30 Ameno 1 0 0 21 85 100 70 88 
178 JANAKI 31 Oligo 1 0 0 21 82 100 70 90 
179 JEYALAXMI 25 Oligo 1 0 0 21 84 120 70 89 
180 RADHA 27 Oligo 1 0 0 19 78 110 70 88 
181 NAVAJOTHI 29 Oligo 1 1 0 23 89 110 80 86 
182 HALIMA 30 Oligo 1 0 0 20 80 110 70 84 
183 USHADEVI 31 Oligo 1 1 0 23 88 100 80 81 
184 AMALA 32 Oligo 1 0 0 21 84 120 70 82 
185 SUSAN PAUL 33 Oligo 1 0 0 20 83 100 70 80 
186 NANCU 28 Oligo 1 0 1 22 87 100 80 90 
187 GANDHIMATHI 26 Oligo 1 0 0 23 86 110 80 80 
188 ROSY 31 Ameno 1 0 0 22 86 110 80 85 
189 NISHA 37 Oligo 1 0 0 19 79 100 70 88 
190 REVATHY 33 Oligo 1 0 0 20 80 110 70 84 
191 BARKATH NISHA 26 Oligo 1 1 0 23 88 120 70 81 
192 JANANI 28 Oligo 1 0 0 22 85 120 70 83 
193 VANMATHI 34 Oligo 1 0 1 23 86 100 70 90 
194 MEENATCHI 37 Ameno 1 0 0 23 88 120 70 78 
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KEY FOR MASTER CHART 
 
MC                     -      Menstrual cycle 
PCO (USG) -  Polycystic  Ovaries in Ultra Sonogram 
BMI - Body mass index in Kg/m2 
SBP - Systolic Blood Pressure in mmHg  
H                          - Hirsuitism 
AN                   -   Acanthosis  Nigricans 
DBP - Diastolic Blood Pressure in mmHg 
FBS - Fasting Blood Sugar 
TGL - Triglycerides in mg/dl 
HDL - High Density Lipoprotein in mg/dl 
WC  - Waist circumference in cm 
0ligo                  -    Oligomenorrhoea 
Ameno              -     Amenorrhoea 
0                        -   Absent 
1                         -  Present                                  
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